Early-life chemical exposures and risk of metabolic syndrome

Nicole E De Long
Alison C Holloway
Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada

Abstract: The global prevalence of obesity has been increasing at a staggering pace, with few indications of any decline, and is now one of the major public health challenges worldwide. While obesity and metabolic syndrome (MetS) have historically thought to be largely driven by increased caloric intake and lack of exercise, this is insufficient to account for the observed changes in disease trends. There is now increasing evidence to suggest that exposure to synthetic chemicals in our environment may also play a key role in the etiology and pathophysiology of metabolic diseases. Importantly, exposures occurring in early life (in utero and early childhood) may have a more profound effect on life-long risk of obesity and MetS. This narrative review explores the evidence linking early-life exposure to a suite of chemicals that are common contaminants associated with food production (pesticides; imidacloprid, chlorpyrifos, and glyphosate) and processing (acrylamide), in addition to chemicals ubiquitously found in our household goods (brominated flame retardants) and drinking water (heavy metals) and changes in key pathways important for the development of MetS and obesity.

Keywords: obesity, pesticides, polybrominated diphenyl ethers, heavy metals, acrylamide, endocrine-disrupting chemicals

Introduction

The global prevalence of obesity has been increasing at a staggering pace, with few indications of any decline, and is now one of the major public health challenges worldwide. Most alarmingly, the list of adverse consequences related to overweight and obesity continues to grow.1–3 It is well accepted that obesity is a risk factor for other metabolic abnormalities, including an increased risk of metabolic syndrome (MetS).4 MetS is a cluster of interrelated metabolic risk factors. MetS as defined by a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, the National Heart, Lung, and Blood Institute, the American Heart Association, the World Heart Federation, the International Atherosclerosis Society, and the International Association for the Study of Obesity includes three of the following five clinical findings: elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose.4 Many of these components of MetS are interrelated, for example, obesity is strongly related to insulin resistance, which is a well-established risk factor for type 2 diabetes.5 The worldwide prevalence estimates vary, but the International Diabetes Federation estimates that one-quarter of adults worldwide have MetS.6 Most alarmingly, people with MetS have a significantly increased risk of developing chronic metabolic diseases, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and cardiovascular disease.7 In addition, obesity has been associated...
with cancer, rheumatoid arthritis, infertility, and depression, among others.5–10 The path to MetS is complex, but there is now compelling evidence from human epidemiological studies and animal experiments to support the hypothesis that exposure of the fetus to certain hormonal, nutritional, metabolic, and environmental conditions may permanently alter the physiology of the resulting offspring and lead to an increased risk of chronic metabolic disease in later life. Clearly, understanding the environmental factors that contribute to the rise in obesity and MetS is critically important.

**Endocrine-disrupting chemicals (EDCs) as metabolic disruptors**

Although the obesity epidemic has historically thought to be largely driven by increased caloric intake and lack of exercise, this is insufficient to account for the observed changes in disease trends. There is now considerable evidence to suggest that early-life exposure to synthetic chemicals in our environment plays an important role in the global epidemic of obesity and MetS. The number of new chemicals that are synthesized and marketed increases exponentially each year; from 2005 to 2015, the number of chemicals registered by the Chemical Abstract Service increased from 25 to 100 million substances.11,12 Introduction of chemicals into the environment (aquatic and terrestrial) occurs from industry and manufacturing practices, agricultural use, and human activity (eg, the use of medications, personal care products, and cleaning products). There is now compelling evidence in mammals that exposure to environmental pollutants can alter endogenous hormonal axes. These chemicals have been termed endocrine disruptors. Historically, research attention has focused largely on the ability of these xenobiotic compounds to alter estrogenic and/or androgenic pathways by acting as agonists/antagonists at hormone receptors, altering the number of hormone receptors in a cell-specific manner or causing perturbations in circulating concentrations of the endogenous hormones.13–18 More recently, however, there has been an increased awareness that these same chemicals can also disrupt metabolic homeostasis. There are now substantial evidence from human epidemiological studies to be associated with increased risk of obesity, and it has also been shown to have direct effects on adipose tissue development (adipogenesis) along with pancreas development and function, leading to an obese, insulin-resistant phenotype.31–33 Similarly, phthalates have also been associated with an increased risk of obesity due to their direct effects on liver function (hepatic fat accumulation) and their ability to disrupt thyroid function (dysregulation of energy balance and metabolism).34–36

It is clear that the mechanisms leading to MetS following early-life exposure to chemicals in our environment are diverse and multidimensional. The goal of this review is to highlight evidence linking early-life exposure to chemicals in our environment with MetS in the progeny into adulthood. There is considerable evidence linking exposure to polyaromatic hydrocarbons, bisphenol A, phthalates, perfluorinated chemicals, polychlorinated biphenyls (PCBs),
organochlorine pesticides, and organotins to metabolic perturbations; these chemicals have been recently reviewed in detail elsewhere.\textsuperscript{37-41} In this review, we focus on a suite of chemicals that are common contaminants associated with food production (pesticides and processing (acrylamides), in addition to chemicals ubiquitously found in our household goods (flame retardants) and drinking water (heavy metals). To complete this narrative review, we used PubMed for our overall basic search for articles published in English using keywords related to the exposures of interest (pesticides, imidacloprid, glyphosate, acrylamide, brominated flame retardants, and heavy metals), the timing of exposure (pregnancy, prenatal, and in utero), and the outcomes of interest (birth weight, fetal outcomes, adipose, insulin, glucose, blood pressure, diabetes, and obesity). We included studies conducted in both animals and humans.

**Crop production: pesticides**

The development of new agricultural-related practices has been vital in expanding our food supply and will continue to play a critical role as the world’s population grows. Insecticides, herbicides, and fertilizers have enhanced the stability of the food supply chain, but they may also contribute to chronic metabolic diseases. In this section, we highlight emerging evidence to suggest that commonly used pesticides may also contribute to the increased incidence of MetS.

**Chlorpyrifos**

Chlorpyrifos is an organophosphate insecticide that inhibits acetylcholinesterase activity. Due to its broad spectrum activity against many foliar and soil insects, it is commonly used worldwide for a pest control in a wide range of field crops and fruit.\textsuperscript{42} Estimated usage in Canada is 100,000–500,000 kg/year and in the US is 3.2–4.1 million kg/year.\textsuperscript{42,43} Chlorpyrifos has been detected in aquatic ecosystems and in a range of food types, including fruits, vegetables, grains, beans/nuts/legumes, dairy, and meat/fish/eggs, leading to human exposure as documented by the widespread presence of urinary metabolites of chlorpyrifos in nonoccupationally exposed populations.\textsuperscript{44-46} Chronic occupational exposures to chlorpyrifos have been demonstrated in farmers from Iowa, Vietnam, and Thailand who were found to have significantly higher urinary metabolites of chlorpyrifos and significant transdermal exposure,\textsuperscript{47,48} both of which are likely to have significant adverse health effects.\textsuperscript{49}

The postnatal metabolic effects of chlorpyrifos exposure during pregnancy are largely unknown due to the absence of human epidemiological studies. However, rodent studies suggest that this is an important concern. Prenatal exposure to chlorpyrifos in rats caused hyperlipidemia and hyperinsulinemia, leading to MetS into adulthood.\textsuperscript{50} Moreover, acute and chronic exposures to chlorpyrifos have been shown to be associated with increased body weight, altered lipid homeostasis, and increased blood pressure.\textsuperscript{51-53} Increased fatty acid synthesis and storage have been further substantiated in vitro following chlorpyrifos exposure.\textsuperscript{44} As a result, it is biologically plausible that in humans, early-life exposures to chlorpyrifos may in fact increase the risk of metabolic disturbances. Given its widespread usage and detection in the environment and human samples, further study is warranted.

**Imidacloprid**

Imidacloprid is a neonicotinoid insecticide. These insecticides act as agonists of insect nicotinic acetylcholine receptors (nAChRs). Neonicotinoids are widely used in agricultural crop production; in 2008, neonicotinoids accounted for ~25% of the global insecticide market.\textsuperscript{54} As a result, imidacloprid has been found in terrestrial (soil) and aquatic (surface and groundwater) environments\textsuperscript{56} as well as being widely detected in fruits and vegetables.\textsuperscript{57}

Despite the fact that in vitro studies have demonstrated the potential for significant absorption of imidacloprid in the human intestine\textsuperscript{58} and imidacloprid residues are prevalent in many fruits and vegetables,\textsuperscript{57} there has been limited population-based biological monitoring for imidacloprid exposure. Recently, a small study in nonoccupationally exposed adults (N=52) demonstrated that imidacloprid was present in the urine of 96% of study participants at levels above the limit of detection.\textsuperscript{59} Historically, neonicotinoids were thought to have limited toxicity for humans due to their high specificity toward insect nAChRs. However, it is now clear that these insecticides also have agonist activity at mammalian nAChRs\textsuperscript{60} raising the possibility of human health risks associated with chronic exposure to neonicotinoids. In fact, high dose of imidacloprid (50 mg/kg) induced hepatotoxicity as evidenced by elevated plasma aspartate aminotransferase and alanine aminotransferase levels in rats.\textsuperscript{61} In addition, 20 mg/kg imidacloprid resulted in hepatic necrosis and infiltration of inflammatory markers.\textsuperscript{62} Moreover, given that adipose tissue expresses multiple nAChR genes, it is possible that imidacloprid may affect lipid homeostasis.\textsuperscript{63} Indeed, a recent study has shown that imidacloprid can promote adipocyte differentiation and lipid accumulation in adipocytes (3T3-L1 cells).\textsuperscript{64} While the mechanism(s) have not been clearly
elucidated, it has been suggested that imidacloprid suppresses the expression of antioxidant enzymes implicating oxidative stress as a significant contributor to the observed metabolic perturbations.65

**Glyphosate**

Glyphosate is one of the most commonly used herbicides worldwide. It inhibits 5-enolpyruvylshikimate-3-phosphate (EPSP) in the shikimate pathway; a pathway plants and microorganisms require for the synthesis of the aromatic amino acids phenylalanine, tyrosine, and tryptophan.66 Glyphosate has been identified in surface and groundwater;67,68 however, most nonoccupational exposures occur from consuming foods containing glyphosate residues.59

While there are detection methods available to measure serum concentrations of glyphosate and its metabolite aminomethylphosphonic acid (AMPA), few studies have investigated the transfer of maternal-to-fetal exposure during pregnancy.70–72 A recent systematic review of observational studies investigating prenatal exposure to glyphosate determined that there is insufficient evidence to conclude that glyphosate does or does not affect pregnancy outcomes, including birth weight.73

While the effects of glyphosate on metabolic health in humans have largely not been explored, there are animal and cell culture studies that have investigated the effects of glyphosate on key metabolic pathways. Although glyphosate is thought to have low toxicity to mammals,74 it has recently been shown to cause liver and kidney toxicities at low doses.75 Results suggest that glyphosate exposure caused liver fibrosis and mitochondrial membrane dysfunction. Furthermore, glyphosate has been shown to increase apoptosis and induce oxidative stress in preadipocytes.76,77 Oxidative stress ensues due to mitochondria dysfunction78 and decreased oxidative capacity, which has been shown to impair glucose uptake into adipocytes, promoting hyperglycemia.79 Oxidative stress also disturbs the adipokine production by fat cells, which has been suggested to be an early initiation event in the development of MetS.80 Taken together, these studies suggest that further study of the effects of glyphosate on MetS risk requires further attention.

**Food processing**

It is widely accepted that in recent decades, there has been a significant increase in the consumption of processed foods. Food processing intentionally introduces food additives (eg, food dyes, emulsifiers, preservatives, and artificial sweeteners) but also introduces unwanted contaminants as a result of the packaging process (eg, bisphenol A). There is another group of chemicals that are introduced by the nature of the food processing itself; one of these is acrylamide.

**Acrylamide**

Acrylamide is produced by the reaction between asparagine and sugar molecules and is formed during food processing. Acrylamide is known to cross the placenta81 with nonsignificant amounts transferring to the infant through breast milk.82 Rodent models have demonstrated that prenatal and perinatal acrylamide exposures result in low birth weight offspring that develop signs of liver toxicity and lipid accumulation in postnatal life.83,84 Meanwhile, administration of acrylamide to adult rodents has been shown to increase glycogen content and increase hepatocyte size in addition to causing dysglycemia and elevated serum lipid levels.85 To date, only three studies have investigated the relationship between prenatal acrylamide exposure and fetal growth outcomes in human populations but have, for the most part, shown consistent associations between acrylamide exposure and reduced fetal growth. The MoBa study found that an increased consumption of acrylamide was associated with lower birth weight infants.86 Similarly, the NewGeneris study found that maternal and cord blood levels of acrylamide and its metabolite glycidamide correlated with a reduced birth weight and head circumference.87 Finally, the most recent study found that maternal dietary acrylamide and birth weight showed a significant negative correlation and that dietary intake of acrylamide was significantly higher in small for gestational age (SGA; <10th percentile) newborns.88 Taken together, these results suggest that an increased maternal acrylamide consumption during pregnancy may have the potential to impair fetal growth; however, it still remains to be determined whether SGA as a result of acrylamide exposure in humans is associated with metabolic abnormalities in postnatal life.

**Household exposures**

There is an increasing awareness that there are a wide variety of chemical exposures, which occur in the home including exposure to cleaning and personal care products, to chemicals used in consumer products to make them stain resistant or to meet legislated flammability standards and to chemicals in household dust and drinking water. Of these chemicals, we will focus on the evidence linking exposure to polybrominated diphenyl ethers (PBDEs) (flame retardants) and heavy metals to metabolic disease risk.
PBDEs

PBDEs have been widely used since the 1970s and are frequently found in mixtures of similar chemicals otherwise called congeners. PBDEs are applied to products, such as fabrics, plastics, household appliances, and electronics, to decrease their flammability. As a result, adults and children are chronically exposed to these chemicals through inhalation of contaminated household dust. Exposure also occurs through hand-to-mouth behaviors in adults (ie, biting nails and licking fingers) and toddlers. Serum concentrations of PBDEs have been broadly related to electronic use. More specifically, individuals who used personal computers, audio/video devices, small household appliances, or own flat screen TVs have been shown to have the highest concentration of PBDEs. In the US, PBDE levels in adults range from 30 to 100 ng/g lipid and these values are typically higher in children. PBDEs measured in pregnant women have ranged between 2.44 and 258 ng/g lipid, while the median concentrations remain between 7.7 and 9.97 ng/g lipid. PBDEs have been shown to cross the placenta and the blood–brain barrier, thus having the potential to impact fetal health and development. In fact, comparing the maternal and cord serum, there is evidence to suggest that fetal exposure is greater compared to the maternal exposure. More astonishing is that measurable levels of PBCDs are present in the developing fetus as early at 6.5 weeks.

Prenatal exposure to high levels of PBDEs has been associated with preterm birth (odds ratio =5.6, 95% CI: 2.2, 15.2; P<0.001) while its effects on birth weight have been inconclusive. In regions where the exposure to PBDEs is higher than the US Environmental Protection Agency Reference dose, exposures have reported a positive correlation between PBDE exposure and birth weight and length. While other regions have shown the opposite relationship or no relationship at all. Furthermore, postnatal exposures to maternal PBDEs through breast milk continue to be a significant source of PBDE congeners. Müller et al have comprehensively described the reported levels of PBDE congeners in breast milk from countries around the world. Although levels appear to be decreasing over time, levels remain at a level that is concerning for the long-term health outcomes of exposed infants.

There is evidence to suggest that prenatal PBDE exposure may in fact cause metabolic perturbations in the offspring. The lipophilic PBDE has been shown to accumulate in adipose tissue and liver and to alter lipolysis and insulin signaling favoring an obese phenotype. In addition, animals exposed prenatally to PBDEs had an impaired fetal growth and the subsequent development of obesity and insulin resistance in adulthood. Similarly, the CHAMA-COS study, a longitudinal birth cohort study in California, found that maternal PBDE levels were significantly and differentially associated with weight changes in children at the age of 7 years based on sex. Another study, the Boston Birth Cohort, examined paired maternal cord blood samples and established that PBDE exposure may result in epigenetic modifications at the promoter region of inflammatory markers, thereby increasing the susceptibility to MetS. Therefore, while it remains to be determined whether PBDE exposure during pregnancy has a significant impact on subsequent metabolic perturbations, long-term data suggest that further studies are warranted.

Metals

Lead, mercury, and cadmium are three metals that have been widely used in a number of applications leading to widespread contamination of food, water, soil, and air and frequent detection in biomonitoring studies. For the general population, the most common sources of exposure for these heavy metals are via contaminated air and food, although exposure to tobacco smoke is also a significant source of exposure for cadmium and lead. Although lead levels have been continuously decreasing in North America, a recent study found that >99% of women had detectable blood lead levels during pregnancy. Similarly, the majority of pregnant women had detectable blood levels of cadmium (>95%) and mercury (>85%). Given the widespread exposure to cadmium, mercury, and lead, there have been a number of studies investigating the relationship between maternal body burden of these metals and adverse pregnancy outcomes (eg, spontaneous abortion, stillbirth, preterm labor, and low birth weight). As a result, there are now a number of epidemiological studies, which have reported that exposure to these heavy metals is associated with low birth weight. However, these results are not entirely consistent as a number of other studies have failed to find a similar association.

There have been a limited number of epidemiological studies looking at early-life exposure to heavy metals and metabolic perturbations in the children. The few studies that do exist do not suggest that exposure to heavy metals is associated with an increased risk of obesity but may be associated with other components of the MetS, most notably changes in blood pressure. There are two studies that have examined early-life exposure to metals and the development of obesity in the children. In a Spanish prospective birth cohort, there was no association between early-life exposure to cadmium, mercury, or lead and weight (body mass index Z-score) at the
morning meal.58 In the 2005 Health Examination Survey (HEDS), the rate of obesity among 6–17-year-olds had increased from 10.1% in 1965 to 16.1% in 2005.59 Similarly, a study by Zhang et al.60 found that the prevalence of obesity in 9- to 13-year-old girls in Shanghai had increased from 4.8% in 1989 to 11.6% in 2002.

Conclusion

There is increasing evidence that early-life exposure to environmental chemicals may play a significant role in the global obesity epidemic.37–41 It is important to note that currently, efforts are being made to reduce the exposure to some of these chemicals. For example, the US Pharmacopeia Convention (USP) has announced plans to establish new monitoring for elemental impurities in pharmaceuticals and nutraceuticals. For example, the US Pharmacopeia Convention (USP) has announced plans to establish new monitoring for elemental impurities in pharmaceuticals and nutraceuticals. This initiative is in line with the 2015 Parma Consensus Statement, which highlighted the importance of modifying exposures to mitigate the potential impact of these chemicals on metabolic diseases.133 Although we have focused on select few chemicals with widespread exposure that have not received substantial attention, there are many other chemicals that have been examined in more detail and been shown to cause metabolic perturbations37–41 and many more that have not been evaluated for their ability to disrupt metabolic homeostasis. Therefore, there is clearly an urgent need for a comprehensive research strategy to evaluate the role of environmental chemicals in metabolic diseases.

Disclosure

The authors report no conflicts of interest in this work.

References


113. Patisaul HB, Roberts SC, Mabrey N, et al. Accumulation and endo-
111. Hoppe AA, Carey GB. Polybrominated diphenyl ethers as endocrine

102. Peletier MR, Koo H-C, Gethahun D, Menon R. Does exposure to flame
retardants increase the risk for preterm birth? *J Reprod Immunol.*

retardants (BFRs) in breast milk and associated health risks to nursing

104. Lignell S, Aune M, Darnerud PO, Hanberg A, Larsson SC, Glynn A. Prenatal exposure to polychlorinated biphenyls (PCBs) and polybro-
dinated diphenyl ethers (PBDEs) may influence birth weight among
infants in a Swedish cohort with background exposure: a cross-


levels in breast milk are decreasing in California. *Chemosphere.* 2016;150:505–513.

110. Nash JT, Szabo DT, Carey GB. Polybrominated diphenyl ethers alter hepatic phosphoenolpyruvate carboxykinase enzyme kinetics in male
Wistar rats: implications for lipid and glucose metabolism. *J Toxicol

111. Hoppe AA, Carey GB. Polybrominated diphenyl ethers as endocrine
disruptors of adipocyte metabolism. *Obesity (Silver Spring).* 2007;
15(12):2942–2950.


113. Patisaul HB, Roberts SC, Mabrey N, et al. Accumulation and endo-

polybrominated diphenyl ether exposures and body mass at age 7 years:


as a source of some trace heavy metals and pesticides in man. *Arch

and slurry sampling for the determination of arsenic, cadmium, and
lead in sidestream cigarette smoke by inductively coupled plasma-mass

118. Tsai M-F, Cheung C-L, Cheung TT, Cheung BMY. Continual decrease
in blood lead level in Americans: United States National Health Nutri-
1213–1218.

119. Arbuckle TE, Liang CL, Morisset A-S, et al. Maternal and fetal expo-

120. Rahman A, Kumarasasan P, Gomes J. Infant and mother related out-
comes from exposure to metals with endocrine disrupting properties


122. Agay-Shay K, Martinez D, Valip D, et al. Exposure to endocrine-disrup-
ting chemicals during pregnancy and weight at 7 years of age: a multi-

and weight of 0- to 5-year-old children in Mexico. *Environ Health


metals has a limited effect on blood pressure or kidney function in later

140:205–213.

128. Skörd H, Hawkesworth S, Moore SE, Wagatsuya Y, Kippler M, Vahlter M. Prenatal lead exposure and childhood blood pressure and


maternal blood mercury concentrations with early and mid-childhood

131. Pharmacopeial Convention US [webpage on the Internet]. *USP to

132. China Water Risk [webpage on the Internet]. *New ‘Soil Ten Plan’ To

133. Heindel JJ, vom Saal FS, Blumberg B. Association of prenatal exposure to endocrine-disrupting chemicals and brain size from exposure to metals with endocrine disrupting properties

Dovepress

Publish your work in *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*

*Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.